Compare Enveric Biosciences Inc (ENVB) vs Global X Uranium ETF (URA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Global X Uranium ETF — how do they compare? Enveric Biosciences Inc trades at $1.45 (market cap $5.32M), while Global X Uranium ETF trades at $39.61. The key difference: Global X Uranium ETF is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| ENVB | URA | |
|---|---|---|
Market Cap | $5.32M | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $17.40 | $61.81 |
52-Week Low | $1.28 | $36.45 |
Enterprise Value | $408.82K | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.41, up 6.82% in the last session. The stock shows a bearish technical trend with moving averages signaling sell, but oscillators are neutral. Financially, the company reported a net loss of $8.77M for 2025, with negative ROE and ROA, though it consistently beat EPS expectations. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003.
Outlook is speculative with high risk due to negative profitability and cash burn, offset by strong analyst buy ratings (75%) and positive clinical updates. Key risks include funding needs and drug development hurdles, while catalysts hinge on regulatory milestones and partnership news.
URA (Global X Uranium ETF) trades at $39.67, down 4.52% in the last session amid a bearish technical setup with 17 sell signals versus 3 buy signals. The ETF faces pressure from moving averages but finds some support from oversold RSI levels. Recent news highlights uranium's strategic positioning for AI energy demand and nuclear power's resurgence, though the fund trails pure-miner alternatives that have outperformed with 61% gains.
The ETF's outlook is supported by structural demand from AI data centers and policy tailwinds, including $17.5 billion in U.S. government loans for nuclear projects. However, high expense ratios (0.52%) and competition from more focused uranium funds present risks. Technical weakness suggests near-term consolidation, but long-term nuclear adoption trends offer growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Global X Uranium ETF
URA provides broad exposure to the global uranium industry and nuclear energy sector. Unlike pure-play mining funds, it includes companies involved in nuclear component production and infrastructure, with top 2026 holdings such as Cameco, Oklo, and Uranium Energy Corp.
Read more on URA →
